IMMX Immix Biopharma, Inc.
USHealthcareAs of 2026-07-10 16:00
Why IMMX matters now
Immix Biopharma, Inc. (IMMX) is a US stock in Healthcare. The latest InvestLog snapshot shows $11.11 with +0.18% on the session and $604.4M in market capitalization; recent performance reads 1-month -1.58% and YTD +66.73%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-10.1M, and EPS of $-0.18. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -6.9%.
The latest indexable market news headline is "All You Need to Know About Immix Biopharma (IMMX) Rating Upgrade to Buy" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Buy with a median target of $17.00; recent insider activity includes BUCHAN JANE filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
3.96
P/S
0.00
EV/EBITDA
-11.46
DCF Value
$2.66
FCF Yield
-6.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-73.2%
ROA
-36.5%
ROIC
-42.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-10.1M | $-0.18 |
| Q4 2025 | $0.00 | $-10.7M | $-0.28 |
| FY 2025 | $0.00 | $-29.4M | $-0.89 |
| Q3 2025 | $0.00 | $-7.6M | $-0.24 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$17.00
Target (Median)
$17.00
Target Range
$14.00 - $20.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.10
Immix Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to creating a range of tissue-specific therapies. Operating in both the United States and Australia, their primary focus areas are oncology (cancer) and inflammatory diseases. Their product pipeline includes IMX-110, which is currently undergoing Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and various solid tumors. They are also developing IMX-111, a targeted biologic agent for colorectal cancers, and IMX-120, another tissue-specific biologic designed to address ulcerative colitis and severe Crohn's disease. In a strategic move, the company has forged a clinical collaboration and supply agreement with BeiGene Ltd. This partnership aims to conduct a Phase 1b combination clinical trial, evaluating IMX-110 in conjunction with BeiGene's anti-PD-1 drug, Tislelizumab, for solid tumor indications. Founded in 2012, Immix Biopharma maintains its headquarters in Los Angeles, California.